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Drug discovery and development is a 
complex and time consuming process which 
requires multidisciplinary expertise (Pracha-
yasittikul et al., 2015a). It is true that bioac-
tive compounds will become useless if their 
pharmacokinetic properties are not adequate. 
Pharmacokinetic properties include absorp-
tion (A), distribution (D), metabolism (M), 
excretion (E) and toxicity (T), or ADMET. 
ADMET properties influence clinical effica-
cy and toxicity of drugs, because they deter-
mine how much and how fast the adminis-
tered drug enters the cell to reach the target 
site of action where it exhibits pharmacolog-
ical effects, as well as control drug metabo-
lism and elimination (van de Waterbeemd 
and Gifford, 2003). In clinical aspect, AD-
MET properties determine route of admin-
istration, administered dose, and frequency 
of administration (van de Waterbeemd and 
Gifford, 2003). The ADMET properties are 
affected by many factors including physico-
chemical/molecular properties of the drug 
(van de Waterbeemd et al., 2001) and drug 
transporters (Lee and Kim, 2004; Murakami 
and Takano, 2008; Ueno et al., 2010). There-
fore, understanding the ADMET properties 
of candidate compounds is essential for suc-
cessful drug development in terms of saving 
time and economic cost. In this regard, 
pharmacokinetic properties are important 
factors that need to be considered in early 
stages of drug development to increase the 
success rate and minimize financial cost (van 
de Waterbeemd and Gifford, 2003). Compu-
tational or in silico approaches are effective 
tools for facilitating drug discovery and de-
velopment (Prachayasittikul et al., 2015a). 
Computational methods are employed in 
many stages of drug development process, 
including primary ADMET screening (van 
de Waterbeemd and Gifford, 2003).  
P-glycoprotein (Pgp) is a good example 
of clinical relevant drug transporter (Amin, 
2013; Srivalli and Lakshmi, 2012; Wessler et 
al., 2013) due to its broad-specific nature and 
its influence on ADMET properties of drugs 
(Srivalli and Lakshmi, 2012). Pgp belongs to 
the ATP-binding cassette (ABC) superfamily 
(Hennessy and Spiers, 2007) and is encoded 
by multidrug resistance (mdr) genes. Pgp 
expresses in many pharmacokinetic-related 
organs and physical barriers such as gastro-
intestinal (GI) tract, blood-brain-barrier 
(BBB), kidney, liver, endothelium and pla-
centa (Fardel et al., 2012). Pgp functions to 
limit cellular uptake, distribution, excretion 
and toxicity of a wide range of structurally 
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unrelated hydrophobic substances, pollutants 
and drugs (Amin, 2013) by acting as a unidi-
rectional efflux pump, which extrudes its 
substrate from inside to outside of cells 
(Aller et al., 2009). It is also recommended 
by the Food and Drug Administration (FDA) 
that a screening to ensure whether the candi-
date bioactive compounds are substrates of 
the Pgp should be conducted as early as pos-
sible during drug discovery pipeline (U.S. 
Food and Drug Administration, 2012). Many 
experimental assays are available to deter-
mine interaction of the compounds against 
Pgp transporter (Pgp endpoint), however, 
discordance of experimental condition leads 
to conflict report of the Pgp endpoints (Polli 
et al., 2001). Hence, classification of Pgp-
interacting compounds is challenging (Wang 
et al., 2005) and is a growing research area. 
Recently, many computational approaches 
such as quantitative structure activity rela-
tionship (Ghandadi et al., 2014; Palestro et 
al., 2014; Shen et al., 2014), classification 
models (Adenot and Lahana, 2004; Chen et 
al., 2011; Klepsch et al., 2014; Levatić et al., 
2013; Li et al., 2014a; Penzotti et al., 2002; 
Prachayasittikul et al., 2015b; Wang et al., 
2011), molecular docking (Ghandadi et al., 
2014; Palestro et al., 2014; Zeino et al., 
2014), and substructure analysis (Prachaya-
sittikul et al., 2016; Wang et al., 2011; Klep-
sch et al., 2014) have been successfully em-
ployed to provide deeper understanding 
about this promiscuous protein.  
The importance of Pgp is not only lim-
ited for ADMET issue, but also extended to 
an area of multidrug resistance (MDR) can-
cer (Hennessy and Spiers, 2007). The link-
age between Pgp overexpression and MDR 
cancer has been demonstrated in literatures 
(Abolhoda et al., 1999; Thomas and Coley, 
2003). Increased efflux activity of the cancer 
cell is one of mechanisms behind drug re-
sistance (Schinkel and Jonker, 2012; Szakács 
et al., 2006). The cancer cells derived from 
tissues that naturally express Pgp (i.e., kid-
ney, colon, liver, and pancreas) have high 
potential to develop intrinsic drug resistance, 
even before exposing to anticancer agents 
(Sun et al., 2004). Unlikely, low level of Pgp 
expression is found in an early diagnostic 
stage of cancer cells of non-Pgp expressed 
origin, but Pgp expression increase and the 
resistance is developed after treating with an-
ticancer drugs (Fardel et al., 1996; Thomas 
and Coley, 2003). Besides exposure to anti-
cancer agents, Pgp expression can be in-
duced by hypoxic condition of the cancer 
cells (Trédan et al., 2007). Pgp overexpres-
sion is found in many types (Drach et al., 
1995) and many stages (Krishna and Mayer, 
2000) of cancer cells. In addition, many clin-
ically used anticancer agents are substrates 
of Pgp (Drach et al., 1995). In this regard, 
delivery of the administered anticancer drug 
to target site of action is impaired thereby 
leading to decreased intracellular drug con-
centration and ineffective treatment outcome 
(Srivalli and Lakshmi, 2012). Hence, an in-
hibition of Pgp function is an attractive strat-
egy toward MDR (Szakács et al., 2006). 
Many Pgp inhibitors (including small mole-
cules, natural compounds, and pharmaceuti-
cal excipients (Srivalli and Lakshmi, 2012)) 
have been developed for a combination use 
with anticancer drugs that are substrates of 
the Pgp to combat resistance (Szakács et al., 
2006). However, the outcome remains apart 
from satisfaction (Szakács et al., 2006). 
Antimicrobial resistance is another glob-
al issue with prime concern. Efflux pump is 
noted to be one of the factors contributing to 
drug resistance of microorganisms (Rouveix, 
2007). Similar to MDR cancer, the MDR 
microorganisms express the broad-specific 
Pgp efflux on their components, therefore, a 
wide range of structurally unrelated hydro-
phobic antimicrobials can be extruded out of 
the bacterial cells (Rouveix, 2007). This 
phenomenon limits access of the drug to tar-
get site of action and deteriorates antimicro-
bial effects (Rouveix, 2007). Beside the 
search for novel antimicrobials against re-
sistant strains, the development of efflux in-
hibitors (i.e., Pgp inhibitors) for co-
administration with the currently used anti-
microbials is considered to be an effective 
treatment strategy that could restore and im-
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prove effectiveness of the standard antimi-
crobial agents.  
It should not be overlooked that Pgp 
plays important roles in ADMET profiles of 
the administered drugs. Thus, drug-drug in-
teraction, adverse effects and toxicities are 
the issues that should be concerned when 
many drugs are co-administered (Amin, 
2013; Aszalos, 2007). In particular, dose ad-
justment and monitoring are recommended 
when drugs with narrow therapeutic window 
are co-administered with strong Pgp inhibi-
tors (Wessler et al., 2013).  
In addition to the search of novel Pgp in-
hibitors, modulation of Pgp expression is an-
other strategy towards therapeutics. Abnor-
mal Pgp expression, either increased or de-
creased expression, is noted to be a patholog-
ical factor of many diseases. Overexpression 
of Pgp in blood-brain barrier (BBB) is found 
in non-responsive refractory epilepsy pa-
tients and is noted to be a contributing factor 
of resistance against anti-epileptic drugs 
(Lazarowski et al., 2007; Li et al., 2014b). 
Similar to cancer, Pgp expression is en-
hanced under the hypoxic condition, which 
is triggered by recurrent seizure (Li et al., 
2014b). In this regard, suppression of Pgp 
expression may be an attractive treatment 
choice.  
Besides degenerate effects, Pgp is also 
noted for its protective roles. Protective role 
of Pgp is demonstrated in Alzheimer’s dis-
ease (AD) and placenta protective mecha-
nism. Amyloid-β is a pathologic protein of 
AD and its accumulation leads to neuronal 
damages (Hardy and Selkoe, 2002). Pgp ef-
flux pump facilitates clearance of amyloid-β 
from the brain and plays critical role in path-
ogenesis and progression of AD (Kuhnke et 
al., 2007; Lam et al., 2001). Pgp expression 
was found to be inversely correlated with 
amyloid-β deposition (Cirrito et al., 2005; 
Hartz et al., 2010; Vogelgesang et al., 2002). 
Thus, increasing cerebrovascular Pgp ex-
pression is suggested to be an alternative 
therapeutic target for treatment and delay 
progression of AD (Brenn et al., 2014). 
Likewise, placental Pgp efflux prevents fetus 
from xenobiotics, toxicants and drugs (Anger 
et al., 2012). The protective effect of placen-
tal Pgp is correlated with level of Pgp ex-
pression. While hypoxic condition provoked 
increased Pgp expression (Trédan et al., 
2007), oxidative stress environment is noted 
to suppress expression and inhibit efflux 
function of Pgp (Li et al., 2011; Wang et al., 
2009). Oxidative stress is one of the most 
common factors contributing to placental in-
juries and other harmful effects during preg-
nancy (Myatt and Cui, 2004). Recent study 
revealed that placental Pgp expression is de-
creased under oxidative stress condition, and 
the level of Pgp expression can be restored 
with antioxidant agent (Li et al., 2014c). 
Hence, upregulation of placental Pgp expres-
sion may be a strategy for preventing ad-
verse conditions and diseases in pregnancy 
(Li et al., 2014c).  
In summary, Pgp is a drug transporter of 
clinical importance in which many aspects of 
this transporter and its interacting ligands are 
need to be fully elucidated. Clinical rele-
vance of Pgp and therapeutic applications of 
its interacting ligands render the study re-
garding this transporter an active research 
area with continual interest. The study relat-
ing to Pgp expression also could be of great 
benefit for understanding the unsolved prob-
lems. In clinical aspect, adjustment of dosing 
regimen and careful drug monitoring also 
take part in an effective treatment along with 
a maximum safety. 
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